Markets punish companies for regulatory headlines before any real guidance. Feels like we’re rewarding fear and ignoring fundamentals.
Are we sure this isn’t just earnings pressure and guidance whiplash? What’s the actual timeline for those HRT approvals and peptide sales?
Peptide and HRT space is tightly regulated; compliance risk is real.
Feels like management’s trying to dodge questions instead of addressing them. Guidance blackout usually means trouble, not just a strong print.
So basically NVDA is skipping guidance due to legal issues, but still expects strong results—does that mean QQQ gets hit less than expected?
I’m holding NVDA and a small QQQ position; results will help, but I’m bracing for choppy days around guidance.
Everyone cheering BTC again, but I’m not convinced. If it’s just liquidity chasing ETH and SOL, the bounce could fade fast. Spot volumes look decent, but futures dominance and on-chain metrics haven’t flipped yet.
Holding BTC and SOL; riding this wave.
Feels like BTC’s momentum is back, but I’m still cautious. Might nibble if it retests last week’s support.
